Sartorius AG (GB:0NIQ)
LSE:0NIQ
0NIQ Stock Chart & Stats
€196.40
€3.40(1.81%)
At close: 4:00 PM EST
€196.40
€3.40(1.81%)
Day’s Range― - ―
52-Week Range€131.40 - €208.00
Previous CloseN/A
Volume8.00
Average Volume (3M)266.00
Market Cap
€12.99B
Enterprise Value€18.63B
Total Cash (Recent Filing)€541.40M
Total Debt (Recent Filing)€4.45B
Price to Earnings (P/E)110.2
Beta1.79
Next Earnings
Apr 23, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend Yield0.39%
Share Statistics
EPS (TTM)1.26
Shares Outstanding37,440,000
10 Day Avg. Volume141
30 Day Avg. Volume266
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€246.00Price Target Upside25.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)5.57
Revenue Forecast (FY)€3.76B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables MomentumSustained mid-teens growth in consumables and a book-to-bill above 1 indicate a large installed base and repeat-purchase dynamics. That recurring revenue underpins predictable top-line and margin resilience across cycles, supporting durable cash generation and pricing leverage over months to years.
Bioprocess Market LeadershipHigh single-digit growth and >30% underlying EBITDA margin in Bioprocess Solutions reflect a strong market position and scalable, high-margin offerings. Dominance in bioprocess consumables and systems supports long-term profitability, cash flow potential, and strategic optionality versus peers.
Product Innovation & Capacity BuildOngoing product launches, partnerships, acquisitions and factory expansions extend the product pipeline and addressable market. These structural investments strengthen the consumables install base, support future attach rates and reduce execution risk of scaling revenue and margins over the coming 2–6 months and beyond.
Bears Say
Elevated LeverageLeverage remains meaningfully elevated for a med-tech tools business, limiting financial flexibility. Even with recent deleveraging, sustained high net leverage increases interest exposure and reduces capacity for opportunistic M&A, capital returns or cushioning versus cyclical demand shocks.
Weakened Cash ConversionMaterial declines in operating cash flow and FCF reduce self-funding ability for capex and debt paydown. Weak cash conversion increases reliance on external financing or slower deleveraging, raising execution risk if margin or revenue assumptions slip over the next several quarters.
LPS & Equipment Demand SoftnessFlat lab-products growth and margin pressure from mix and investment are structural drags on diversification. Continued softness in equipment capex delays upstream installs that drive future consumables consumption, potentially slowing sustainable group growth and margin expansion over the medium term.
Sartorius News
0NIQ FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest share price was €131.40 and its highest was €208.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €12.99B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Apr 23, 2026 which is in 28 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Feb 03, 2026. The company reported €1.26 earnings per share for the quarter, missing the consensus estimate of €1.312 by -€0.052.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.39%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.27.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.26 in its last earnings report, missing expectations of €1.312. Following the earnings report the stock price went up 4.158%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in GB:0NIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€246.00 (25.25% Upside)
€246.00 (25.25% Upside)
Insider Transactions
Bought Shares
Worth €286.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.90%
12-Months-Change
Fundamentals
Return on Equity
5.77%
Trailing 12-Months
Asset Growth
-3.82%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
0NIQ Stock 12 Month Forecast
Average Price Target
€246.00
▲(25.25% Upside)
Technical Analysis
Carl Zeiss Meditec
―
Fresenius Medical Care AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
Merck KGaA
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---